Trevi Therapeutics Initiates Multiple Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy TRVI?
"We are entering an important phase of execution for Trevi, with study initiations anticipated across our chronic cough programs," said Jennifer Good, President and CEO of Trevi Therapeutics. "Following a very productive End-of-Phase 2 meeting with the FDA on our lead program in IPF-related chronic cough, we are excited to initiate multiple clinical trials this quarter, including our first Phase 3 in IPF-related chronic cough and our Phase 2b in RCC. With an expected cash runway into 2030, we are well-positioned to execute on our development strategy and advance towards a potential FDA submission in IPF-related chronic cough. We believe successful execution of our strategy would establish Trevi as the leader in providing best-in-class therapy in chronic cough indications with significant unmet needs and no FDA-approved therapies."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRVI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRVI
Wall Street analysts forecast TRVI stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.500
Low
16.00
Averages
21.22
High
25.00
Current: 14.500
Low
16.00
Averages
21.22
High
25.00
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trevi Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Initiation: Trevi Therapeutics plans to initiate two studies related to idiopathic pulmonary fibrosis (IPF) chronic cough in Q1 2026, with the second study expected to start in the second half of the year, which will enhance the company's competitive position in the chronic cough market.
- Improved Financial Position: As of the end of Q1 2026, the company reported approximately $172 million in cash and cash equivalents, and the $162 million net proceeds from the April 2026 equity offering will extend the cash runway into 2030, alleviating financial pressure.
- R&D Strategy Adjustment: Management has decided to shift the study design for non-IPF-ILD chronic cough to an adaptive Phase II/III study, with plans to submit the protocol to the FDA in the second half of the year, which will help improve the likelihood of clinical trial success.
- Market Outlook: Management emphasized a focus on trial initiations and interim milestones rather than revenue or EPS guidance, reflecting the company's confidence in execution and capitalization, particularly regarding the upcoming RCC Phase IIb trial and SSRE results release.
See More
Trevi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Trevi Therapeutics reported a Q1 non-GAAP EPS of -$0.09, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of Q1 2026, the company held $171.8 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the coming years despite ongoing profitability issues.
- Funding Impact: Following the completion of its underwritten common stock offering in April 2026, Trevi expects its current cash resources to extend its runway into 2030, providing essential financial support for future R&D and operational needs.
- Clinical Trial Plans: Trevi is planning two pivotal phase III trials for IPF-related chronic cough, and while execution risks remain, FDA alignment offers confidence for its future development.
See More
Trevi Therapeutics Prices $150 Million Public Offering Amid Bullish Market Sentiment
- Successful Public Offering: Trevi Therapeutics priced its $150 million public offering at $13 per share, planning to issue 11.6 million shares, with the offering expected to close around April 20, 2026, indicating strong market confidence in its future prospects.
- Stock Price Surge: Following the public offering announcement, Trevi's shares jumped 5% on Friday to an all-time high, with nearly a 20% increase over the past five trading sessions, reflecting investor optimism about the company's potential growth.
- Clinical Trial Plans: Trevi plans to launch two late-stage clinical trials for its chronic cough treatment Haduvio in the second quarter of 2026, with the first trial enrolling around 300 patients and the second about 130, aimed at validating the drug's safety and efficacy.
- Market Sentiment Shift: According to Stocktwits data, retail investor sentiment flipped from 'bearish' to 'bullish' a day before the offering, with message volumes soaring 600%, demonstrating strong market interest and confidence in Trevi's future developments.
See More
Trevi Therapeutics Prices Public Offering at $13 per Share
- Public Offering Pricing: Trevi Therapeutics announced the pricing of 11,600,000 shares at $13 each, expecting to raise $150 million, which will bolster its financial position in the biopharmaceutical sector.
- Stock Performance: Following the announcement, Trevi's shares reached a 52-week high of $14.75, reflecting positive market sentiment towards its new therapy, although pre-market trading saw a decline to $13.88, down 4.54%.
- Underwriter Option: Underwriters have a 30-day option to purchase an additional 1,740,000 shares at the public offering price, enhancing the company's fundraising capabilities to support its research projects.
- R&D Progress: Trevi is developing Haduvio (oral nalbuphine extended release), the first investigational therapy showing significant efficacy in clinical trials for idiopathic pulmonary fibrosis and refractory chronic cough, indicating substantial market potential.
See More
Trevi Therapeutics Prices $150 Million Public Offering of Common Stock
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Arrangement: The offering is managed by top-tier firms including Morgan Stanley, Leerink Partners, Cantor, and Stifel, with Oppenheimer & Co. as the lead manager, indicating robust institutional support for the financing effort.
- Additional Share Option: Trevi has granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, a strategy that could further enhance the company's capital-raising capabilities and meet market demand.
- Expected Closing Date: The offering is anticipated to close around April 20, 2026, subject to customary closing conditions, and if successful, will provide critical funding for the company's ongoing research and market expansion efforts.
See More
Trevi Therapeutics Raises $150 Million in Public Offering
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market confidence in its investigational therapy Haduvio™.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering, indicating robust professional support in capital markets and enhancing investor trust in the company's future prospects.
- Additional Share Option: Trevi granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, providing flexibility that could further enhance the company's financing capabilities to support R&D and market expansion.
- Regulatory Compliance: The offering is conducted under a shelf registration statement on Form S-3 filed on November 13, 2025, ensuring compliance and providing transparent disclosures to investors, thereby strengthening market confidence in the company's governance.
See More
Trevi Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Initiation: Trevi Therapeutics plans to initiate two studies related to idiopathic pulmonary fibrosis (IPF) chronic cough in Q1 2026, with the second study expected to start in the second half of the year, which will enhance the company's competitive position in the chronic cough market.
- Improved Financial Position: As of the end of Q1 2026, the company reported approximately $172 million in cash and cash equivalents, and the $162 million net proceeds from the April 2026 equity offering will extend the cash runway into 2030, alleviating financial pressure.
- R&D Strategy Adjustment: Management has decided to shift the study design for non-IPF-ILD chronic cough to an adaptive Phase II/III study, with plans to submit the protocol to the FDA in the second half of the year, which will help improve the likelihood of clinical trial success.
- Market Outlook: Management emphasized a focus on trial initiations and interim milestones rather than revenue or EPS guidance, reflecting the company's confidence in execution and capitalization, particularly regarding the upcoming RCC Phase IIb trial and SSRE results release.
See More
Trevi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Trevi Therapeutics reported a Q1 non-GAAP EPS of -$0.09, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of Q1 2026, the company held $171.8 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the coming years despite ongoing profitability issues.
- Funding Impact: Following the completion of its underwritten common stock offering in April 2026, Trevi expects its current cash resources to extend its runway into 2030, providing essential financial support for future R&D and operational needs.
- Clinical Trial Plans: Trevi is planning two pivotal phase III trials for IPF-related chronic cough, and while execution risks remain, FDA alignment offers confidence for its future development.
See More
Trevi Therapeutics Prices $150 Million Public Offering Amid Bullish Market Sentiment
- Successful Public Offering: Trevi Therapeutics priced its $150 million public offering at $13 per share, planning to issue 11.6 million shares, with the offering expected to close around April 20, 2026, indicating strong market confidence in its future prospects.
- Stock Price Surge: Following the public offering announcement, Trevi's shares jumped 5% on Friday to an all-time high, with nearly a 20% increase over the past five trading sessions, reflecting investor optimism about the company's potential growth.
- Clinical Trial Plans: Trevi plans to launch two late-stage clinical trials for its chronic cough treatment Haduvio in the second quarter of 2026, with the first trial enrolling around 300 patients and the second about 130, aimed at validating the drug's safety and efficacy.
- Market Sentiment Shift: According to Stocktwits data, retail investor sentiment flipped from 'bearish' to 'bullish' a day before the offering, with message volumes soaring 600%, demonstrating strong market interest and confidence in Trevi's future developments.
See More
Trevi Therapeutics Prices Public Offering at $13 per Share
- Public Offering Pricing: Trevi Therapeutics announced the pricing of 11,600,000 shares at $13 each, expecting to raise $150 million, which will bolster its financial position in the biopharmaceutical sector.
- Stock Performance: Following the announcement, Trevi's shares reached a 52-week high of $14.75, reflecting positive market sentiment towards its new therapy, although pre-market trading saw a decline to $13.88, down 4.54%.
- Underwriter Option: Underwriters have a 30-day option to purchase an additional 1,740,000 shares at the public offering price, enhancing the company's fundraising capabilities to support its research projects.
- R&D Progress: Trevi is developing Haduvio (oral nalbuphine extended release), the first investigational therapy showing significant efficacy in clinical trials for idiopathic pulmonary fibrosis and refractory chronic cough, indicating substantial market potential.
See More
Trevi Therapeutics Prices $150 Million Public Offering of Common Stock
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Arrangement: The offering is managed by top-tier firms including Morgan Stanley, Leerink Partners, Cantor, and Stifel, with Oppenheimer & Co. as the lead manager, indicating robust institutional support for the financing effort.
- Additional Share Option: Trevi has granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, a strategy that could further enhance the company's capital-raising capabilities and meet market demand.
- Expected Closing Date: The offering is anticipated to close around April 20, 2026, subject to customary closing conditions, and if successful, will provide critical funding for the company's ongoing research and market expansion efforts.
See More
Trevi Therapeutics Raises $150 Million in Public Offering
- Offering Size: Trevi Therapeutics announced a public offering of 11,600,000 shares at $13.00 per share, aiming to raise approximately $150 million, reflecting strong market confidence in its investigational therapy Haduvio™.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering, indicating robust professional support in capital markets and enhancing investor trust in the company's future prospects.
- Additional Share Option: Trevi granted underwriters a 30-day option to purchase up to 1,740,000 additional shares, providing flexibility that could further enhance the company's financing capabilities to support R&D and market expansion.
- Regulatory Compliance: The offering is conducted under a shelf registration statement on Form S-3 filed on November 13, 2025, ensuring compliance and providing transparent disclosures to investors, thereby strengthening market confidence in the company's governance.
See More
